StocksInsight

CAH Stock vs the S&P 500: Returns, Risk and Crash History

Cardinal Health, Inc., healthcare (market value $65.0 billion), an S&P 500 member: how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

Key takeaways

  • CAH returned +479.9% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it beat the index.
  • Its 5-year Sharpe ratio was 1.33 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −58.3% in the global financial crisis (2007–09) (S&P 500: −56.5%).
  • Five‑year volatility was 24.5% and beta 0.52.
  • 18 analysts rated it in the past year; 89% of their latest calls were Buy.
  • CAH beat earnings estimates in 12 of its last 12 reports; the stock moved 5.9% on average, up or down, around each report.

What do the best‑ranked analysts on CAH say now? See it in Exent Gems →

Did CAH beat the S&P 500?

Over the 5 years to Oct 30, 2026, Cardinal Health, Inc. (CAH) returned +479.9% including dividends, versus +75.9% for the S&P 500 (SPY). It beat the index by 404.0 percentage points, or +42.1% a year against +12.0%.

PeriodCAHS&P 500CAH per yearS&P 500 per yearResult
1 year+32.5%+12.0%+32.5%+12.0%Beat
3 years+187.3%+87.4%+42.2%+23.3%Beat
5 years+479.9%+75.9%+42.1%+12.0%Beat
10 years+380.1%+316.3%+17.0%+15.3%Beat
  • 1 year
    CAH
    +32.5%
    S&P 500
    +12.0%
    CAH per year
    +32.5%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 3 years
    CAH
    +187.3%
    S&P 500
    +87.4%
    CAH per year
    +42.2%
    S&P 500 per year
    +23.3%
    Result
    Beat
  • 5 years
    CAH
    +479.9%
    S&P 500
    +75.9%
    CAH per year
    +42.1%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 10 years
    CAH
    +380.1%
    S&P 500
    +316.3%
    CAH per year
    +17.0%
    S&P 500 per year
    +15.3%
    Result
    Beat

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

CAH is in the S&P 500 (members as of Oct 20, 2026); the list shows every member’s return against the index.

What Wall Street analysts say about CAH

In the 12 months to 30 days ago, 18 analysts published 136 ratings on CAH. Their latest calls were 89% Buy, 11% Hold and 0% Sell. 6 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $288.27 (range $265.00–$321.00), +3.6% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
??????5.0★63.4%
Allen LutzBank of America Securities4.9★60.1%
Eric ColdwellRobert W. Baird4.7★54.8%
Lisa GillJ.P. Morgan4.7★51.3%
George HillDeutsche Bank 4.6★62.2%

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on CAH are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

CAH returns by year vs the S&P 500

CAH beat the S&P 500 in 3 of the 9 full calendar years shown.

YearCAHS&P 500Difference
2026 (to Oct 30, 2026)+23.0%+11.7%+11.3%
2025+76.3%+17.7%+58.6%
2024+19.0%+24.9%−5.9%
2023+34.1%+26.2%+7.9%
2022+54.1%−18.2%+72.3%
2021−0.4%+28.7%−29.1%
2020+10.1%+18.3%−8.2%
2019+18.0%+31.2%−13.2%
2018−24.5%−4.6%−19.9%
2017−12.7%+21.7%−34.4%

CAH risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, CAH had a Sharpe ratio of 1.33 against 0.58 for the S&P 500, so it earned more return per unit of risk than the index. Its annualized volatility was 26.6% and its beta 0.52: it tended to move about 0.5× as much as the market.

MetricCAHS&P 500
Annual return+42.1%+12.0%
Volatility (annualized)26.6%15.5%
Sharpe ratio1.330.58
Sortino ratio3.310.91
Max drawdown (month-end)−15.7%−23.9%
Beta to the S&P 5000.521.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How CAH behaved in past crashes

CAH’s deepest fall in the crises below was −58.3% in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisCAHS&P 500Loss on $100,000
Global financial crisis (2007–09)−58.3%−56.5%−$58,280
2018 trade-war selloff−25.5%−20.2%−$25,510
COVID crash (Feb–Mar 2020)−32.1%−34.1%−$32,140
2022 inflation bear market−20.9%−25.4%−$20,950
2025 tariff selloff−9.9%−19.0%−$9,860
WindowCAH max drawdown
Last 1 year−20.4%
Last 3 years−20.4%
Last 5 years−21.0%
Last 10 years−53.0%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with CAH, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, CAH’s correlation with the S&P 500 was 0.30, with the Nasdaq‑100 0.17, with long Treasuries (TLT) 0.27 and with gold (GLD) 0.01.

Adding a 5% CAH position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.1%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
GOOGL−0.11SYK0.55
QCOM−0.10MCK0.51
PFE−0.08HCA0.51
META−0.08ECL0.48
APP−0.07CSX0.47

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest CAH upgrades, downgrades and price‑target changes

DateRating and targetAnalyst
Nov 10Target raised
Buy
Target $320, was $260
Allen Lutz
Bank of America Securities
Nov 10Target raised
Hold
Target $286, was $260
Lisa Gill
J.P. Morgan
Nov 5Target raised
Buy
Target $305, was $248
Eric Coldwell
Robert W. Baird
Oct 20Target raised
Buy
Target $280, was $250
Steven Valiquette
Mizuho Securities
Oct 16Target raised
Buy
Target $295, was $274
Kevin Caliendo
UBS

Named analysts’ rating and price‑target changes on CAH in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

Do analysts get CAH right?

Of the 328 analyst price targets on CAH set from 2019 until a year ago, 90.2% were reached within 12 months (data to Oct 20, 2026), 21.6 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 78 days. The median target sat 11.0% above the share price on the day it was set.

Where analysts said CAH would be by now: a year ago, 10 analysts had a price target on CAH, and the median of their latest targets was $220.00. On Oct 20, 2026 CAH closed at $257.53, 17.1% above it.

90.2%of targets reached within 12 monthsMedian stock: 68.6%
78 daysmedian time to reach a target
+17.1%price now vs the median target set a year ago
AfterCallsMove on the call3 months vs S&P 500
Upgrades of CAH20+2.0%+5.2%
Upgrades, all stocks11,514+2.5%+3.4%
Downgrades of CAH6−6.5%−6.9%
Downgrades, all stocks10,700−3.0%−1.6%

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on CAH through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?

How CAH moves after earnings

CAH beat the consensus earnings‑per‑share estimate in 12 of its last 12 quarterly reports, through the one on Aug 11, 2026, and the revenue estimate in 7 of 12. From the close before each report to the close after it, the stock moved 5.9% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 6 of the 12 reports. In 6 of the 12 beats the stock still fell.

12/12earnings beats
±5.9%average move per report
6/12reports followed by a rise
ReportEPS vs estimateRevenue vs estimateStock move
Aug 11, 2026$2.91 vs $2.42−2.3%−1.3%
Apr 30, 2026$3.17 vs $2.79−1.9%−3.7%
Feb 5, 2026$2.63 vs $2.34+0.8%+9.4%
Oct 30, 2025$2.55 vs $2.18+8.1%+16.0%
Aug 12, 2025$2.08 vs $2.04−1.2%−6.1%
May 1, 2025$2.35 vs $2.17−0.9%+5.8%
Jan 30, 2025$1.93 vs $1.74+0.4%−3.2%
Nov 1, 2024$1.88 vs $1.62+2.7%+3.1%

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings

Where CAH’s revenue comes from

In fiscal 2026 (the year to Jun 30, 2026), CAH’s largest reported region was the United States, with 99.3% of its $254.3 billion revenue. By region: United States 99.3%; Non-US 0.7%.

By business, the largest segment was Pharmaceutical Member, with 92.3% of $254.3 billion revenue (+14.8% on the year before).

  • United States99.3%
  • Non-US0.7%
SegmentRevenueShareGrowth
Pharmaceutical Member$234.8 billion92.3%+14.8%
GMPD$12.7 billion5.0%+0.7%
Other Operating Segment$6.8 billion2.7%+26.2%

From CAH’s annual filings; segment growth compares fiscal 2026 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?

Members of Congress who traded CAH

As of Oct 20, 2026, 11 members of Congress had disclosed 29 trades in CAH (19 buys and 10 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated Mar 27, 2026.

Trade dateMemberTypeAmount
Mar 27, 2026Alan ArmstrongBuy$1,001–$15,000
Oct 24, 2025Marjorie Taylor GreeneBuy$1,001–$15,000
Sep 5, 2025Ro KhannaSale$1,001–$15,000
May 14, 2025Marjorie Taylor GreeneBuy$1,001–$15,000
May 5, 2025Marjorie Taylor GreeneBuy$1,001–$15,000
Apr 8, 2025Rob BresnahanBuy$1,001–$15,000
Mar 17, 2025Marjorie Taylor GreeneBuy$1,001–$15,000
Jan 21, 2025Marjorie Taylor GreeneBuy$1,001–$15,000
Sep 20, 2024Marjorie Taylor GreeneBuy$1,001–$15,000
Sep 4, 2024John JamesSale$1,001–$15,000

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades

Are CAH insiders buying or selling?

In the 12 months to Oct 20, 2026, CAH insiders made no open‑market purchases and 35 sales worth $61.6 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Nov 15, 2022.

After the 6 insider purchases of $10,000 or more since 2012, CAH beat the S&P 500 by an average of 26.3 percentage points over the next 12 months; 83% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

Q4 ’24
Q1 ’25
Q2 ’25
Q3 ’25
Q4 ’25
Q1 ’26
Q2 ’26
Q3 ’26
DateInsiderRoleValue
Nov 15, 2022Brennan MichelleDirector$14,944
Nov 14, 2022Brennan MichelleDirector$15,260
Nov 10, 2022Brennan MichelleDirector$11,961
Jan 18, 2022Snow Ola MChief Human Resources Officer$5,949
Oct 15, 2021Snow Ola MChief Human Resources Officer$10,363

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?

How much of CAH is sold short?

As of the Sep 30, 2026 settlement date, 3.19% of CAH’s float was sold short: 7.4 million shares, or 3.4 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 2.86%. The median across the 997 US stocks Exent tracks was 4.77%, so CAH is less heavily shorted than most.

  • Apr 30, 20262.62%
  • May 29, 20263.42%
  • Jun 30, 20263.06%
  • Jul 31, 20262.85%
  • Aug 31, 20262.91%
  • Sep 30, 20263.19%

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks

How many institutions own CAH?

At the end of Q2 2026 (Jun 30, 2026), 1,550 institutions reported holding CAH in 13F filings, up 62 from the quarter before and up from 1,308 a year earlier. Their reported holdings add up to 88.3% of CAH’s shares. In the quarter 713 institutions added to their positions and 573 cut them.

1,55013F holders
170new positions
104positions closed
88.3%of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling

Is CAH diluting shareholders?

CAH’s diluted share count fell 19.4% over the five fiscal years to fiscal 2026 and fell 2.1% in fiscal 2026 alone. Each share now owns a larger slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $367.0 million in fiscal 2026, 0.1% of revenue. CAH spent $1.4 billion buying back shares, a buyback yield of 2.57% of its market value; stock pay equaled 27.0% of the buybacks.

−2.1%share count, 1 year
−19.4%share count, 5 years
0.1%stock pay as % of revenue
2.57%buyback yield

Weighted‑average diluted shares from CAH’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained

CAH financial health scores

In Exent’s Oct 20, 2026 snapshot, CAH’s Altman Z‑score was 5.11, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 7 out of 9; 40% of scored stocks reach 7 or more.

5.11Altman Z‑score: safe zone
7/9Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?

What CAH talks about on earnings calls

On its latest earnings call (Aug 11, 2026), CAH’s executives and analysts did not mention AI, against 0 on the call before (Apr 30, 2026); the average across 455 S&P 500 calls that quarter was 12.9. After AI, the most mentioned topic was tariffs (22).

MentionsAug ’26Apr ’26Feb ’26Oct ’25
AI0010
AI agents0000
Data centers0000
Tariffs221536
China0000
Recession0000
  • AI
    Aug ’26
    0
    Apr ’26
    0
    Feb ’26
    1
    Oct ’25
    0
  • AI agents
    Aug ’26
    0
    Apr ’26
    0
    Feb ’26
    0
    Oct ’25
    0
  • Data centers
    Aug ’26
    0
    Apr ’26
    0
    Feb ’26
    0
    Oct ’25
    0
  • Tariffs
    Aug ’26
    22
    Apr ’26
    15
    Feb ’26
    3
    Oct ’25
    6
  • China
    Aug ’26
    0
    Apr ’26
    0
    Feb ’26
    0
    Oct ’25
    0
  • Recession
    Aug ’26
    0
    Apr ’26
    0
    Feb ’26
    0
    Oct ’25
    0

Word counts in the full transcript of each call, prepared remarks and Q&A, newest first. “AI” also counts generative AI and large language models; “AI agents” counts agentic AI. Which companies talk most about AI?

Which ETFs hold CAH?

As of Oct 20, 2026, 58 of the 304 ETFs Exent tracks held CAH. Its largest weight is in DSTL (Distillate U.S. Fundamental Stability & Value ETF), at 1.19% of the fund.

ETFFundWeight of CAH
DSTLDistillate U.S. Fundamental Stability & Value ETF1.19%
COWZPacer US Cash Cows 100 ETF1.09%
XLVState Street Health Care Select Sector SPDR ETF0.92%
VOEVanguard Mid-Cap Value Index Fund0.88%
IWPiShares Russell Mid-Cap Growth ETF0.81%
VHTVanguard Health Care Index Fund ETF Shares0.73%
CLSEConvergence Long/Short Equity ETF0.66%
VOVanguard Mid-Cap Index Fund ETF Shares0.51%

Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?

How much is CAH’s CEO paid?

Jason M. Hollar, CAH’s Chief Executive Officer, received total pay of $22.6 million for fiscal 2026, up 19.0% from $19.0 million for fiscal 2025, according to the company’s proxy statement filed with the SEC on Sep 21, 2026. 72% of it came as stock and option awards, valued when they were granted rather than when they pay out. The median CEO pay across the 378 S&P 500 companies Exent tracks was $17.2 million.

Pay componentAmountShare of total
Salary$1.5 million6.6%
Stock and option awards$16.3 million72.0%
Incentive plan (cash)$4.3 million19.0%
Other$535,6812.4%
Other top executivesRoleTotal pay, 2026
Aaron E. AltChief Financial Officer$6.9 million
Deborah L. WeitzmanChief Executive Officer, Pharmaceutical and Specialty Solutions Segment$6.1 million
Jessica L. MayerChief Legal and Compliance Officer$5.5 million
Stephen M. MasonChief Executive Officer, Global Medical Products and Distribution Segment$5.3 million

Figures from the summary compensation table of the proxy statement; awards count at their grant‑date value, so one large multi‑year grant can make a single year stand out. CEO pay across the S&P 500

Does CAH get federal contracts?

In federal fiscal year 2026 (October 1, 2025 to September 30, 2026), US government agencies obligated $329.9 million in contracts to Cardinal Health, Inc. and its units, according to USAspending.gov, down 29.5% from $468.2 million the year before.

Fiscal yearContract obligations
2026$329.9 million
2025$468.2 million
2024$638.2 million
2023$607.3 million
2022$605.0 million

Contract obligations are what agencies committed in the year, not cash paid; every subsidiary and unit USAspending.gov lists under the parent company is rolled up into one total. Which companies get the most federal contracts?

The right benchmark for CAH

Exent matches every holding to the index with the most similar risk. For CAH that is SPY (the S&P 500). Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other healthcare stocks

TickerName5‑year returnVolatility (5y)
LLYEli Lilly and Company+482.3%32.6%
JNJJohnson & Johnson+92.9%16.8%
ABBVAbbVie Inc.+207.1%23.5%
BSXBoston Scientific Corporation−2.7%27.4%
CORCencora, Inc.+188.1%23.3%
EWEdwards Lifesciences Corporation−23.2%34.2%
CIThe Cigna Group+53.2%28.6%
NTRANatera, Inc.+261.6%57.5%

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check CAH with Exent Gems

Wall Street’s average CAH price target is 3.6% above the latest share price. See what the best‑ranked analysts on CAH say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering CAH are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

Yes. CAH returned +380.1% (+17.0% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

Yes. As of Oct 20, 2026, CAH (Cardinal Health, Inc.) is one of the 503 stocks in the S&P 500.

CAH fell −58.3% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.

CAH fell −32.1% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

CAH fell −20.9% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, CAH’s Sharpe ratio was 1.33 and its Sortino ratio 3.31, versus 0.58 and 0.91 for the S&P 500.

CAH’s 5‑year annualized volatility was 24.5%, higher than the S&P 500’s 17.0%, with a beta of 0.52.

Among large US stocks, the lowest correlations with CAH over the last 60 months were GOOGL (−0.11), QCOM (−0.10), PFE (−0.08). Its correlation with long Treasuries (TLT) was 0.27 and with gold (GLD) 0.01.

CAH beat the consensus earnings-per-share estimate in 12 of its last 12 quarterly reports through Aug 11, 2026, and the revenue estimate in 7 of 12. The stock moved 5.9% on average, up or down, from the close before each report to the close after it.

Jason M. Hollar, CAH’s Chief Executive Officer, received $22.6 million in total pay for fiscal 2026, including a $1.5 million salary and $16.3 million in stock and option awards valued at grant, according to the proxy statement filed with the SEC on Sep 21, 2026. The median S&P 500 CEO received $17.2 million.

Yes. As of Oct 20, 2026, 11 members of Congress had disclosed 29 trades in CAH (19 buys and 10 sales) in STOCK Act disclosures filed with the House and Senate.

As of the Sep 30, 2026 settlement date, 3.19% of CAH’s float was sold short (7.4 million shares, 3.4 days to cover), according to FINRA short-interest reports. A year earlier it was 2.86%.

No. CAH’s diluted share count fell 19.4% over the five fiscal years to fiscal 2026 and fell 2.1% in the latest year. Stock-based compensation was 0.1% of revenue, and buybacks totaled $1.4 billion.

What do the best‑ranked analysts say on CAH now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on CAH are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.